Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution.

Bontjer I, Land A, Eggink D, Verkade E, Tuin K, Baldwin C, Pollakis G, Paxton WA, Braakman I, Berkhout B, Sanders RW.

J Virol. 2009 Jan;83(1):368-83. doi: 10.1128/JVI.01404-08. Epub 2008 Oct 15.

5.

V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.

Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW.

PLoS Pathog. 2007 Aug 24;3(8):e117.

7.

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC, Ketas T, Yuste E, Desrosiers RC, Klasse PJ, Maddon PJ, Olson WC, Moore JP.

Virology. 2007 Apr 10;360(2):329-40. Epub 2006 Nov 28.

8.

Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.

Bontjer I, Melchers M, Eggink D, David K, Moore JP, Berkhout B, Sanders RW.

J Biol Chem. 2010 Nov 19;285(47):36456-70. doi: 10.1074/jbc.M110.156588. Epub 2010 Sep 8.

11.

Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses.

Gzyl J, Bolesta E, Wierzbicki A, Kmieciak D, Naito T, Honda M, Komuro K, Kaneko Y, Kozbor D.

Virology. 2004 Jan 20;318(2):493-506.

12.

[Role of the HIV-1 gp120 V1/V2 domains in the induction of neutralizing antibodies].

Granados-González V, Piedrahita LD, Martínez M, Genin C, Riffard S, Urcuqui-Inchima S.

Enferm Infecc Microbiol Clin. 2009 Nov;27(9):523-30. doi: 10.1016/j.eimc.2008.02.010. Epub 2009 May 1. Review. Spanish.

PMID:
19409660
13.

Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope.

Yang ZY, Chakrabarti BK, Xu L, Welcher B, Kong WP, Leung K, Panet A, Mascola JR, Nabel GJ.

J Virol. 2004 Apr;78(8):4029-36. Erratum in: J Virol. 2006 Apr;80(8):4206.

14.

Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies.

Kang SM, Quan FS, Huang C, Guo L, Ye L, Yang C, Compans RW.

Virology. 2005 Jan 5;331(1):20-32.

15.

Effect of natural HIV-1 envelope V1-V2 sequence diversity on the binding of V3-specific and non-V3-specific antibodies.

Rencher SD, Hurwitz JL.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Oct 1;16(2):69-73.

PMID:
9358100
16.
17.

Design, expression, and immunogenicity of a soluble HIV trimeric envelope fragment adopting a prefusion gp41 configuration.

Qiao ZS, Kim M, Reinhold B, Montefiori D, Wang JH, Reinherz EL.

J Biol Chem. 2005 Jun 17;280(24):23138-46. Epub 2005 Apr 15.

19.

Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.

Sharma VA, Kan E, Sun Y, Lian Y, Cisto J, Frasca V, Hilt S, Stamatatos L, Donnelly JJ, Ulmer JB, Barnett SW, Srivastava IK.

Virology. 2006 Aug 15;352(1):131-44. doi: 10.1016/j.virol.2006.04.030.

20.

Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env.

Georgiev IS, Joyce MG, Yang Y, Sastry M, Zhang B, Baxa U, Chen RE, Druz A, Lees CR, Narpala S, Schön A, Van Galen J, Chuang GY, Gorman J, Harned A, Pancera M, Stewart-Jones GB, Cheng C, Freire E, McDermott AB, Mascola JR, Kwong PD.

J Virol. 2015 May;89(10):5318-29. doi: 10.1128/JVI.03451-14. Epub 2015 Mar 4.

Supplemental Content

Support Center